Reported 28 days ago
JPMorgan has initiated coverage on Viking Therapeutics (VKTX), giving it an Overweight rating and setting a price target of $80 per share. Following this announcement, Viking's stock rose by 10%, currently trading above $60. The report also touched on competitor plans from Novo Nordisk and Roche regarding obesity treatments. Matt Higgins from RSE Ventures expressed confidence that Viking Therapeutics will take a leadership role in the GLP-1 weight-loss market.
Source: YAHOO